See all the latest videos and articles patriots need to watch and read at Discern.tv.
This week, the CEO of Pfizer said that the pharmaceutical giant’s COVID-19 vaccine trials on children aged 5-11 could soon be wrapping up and their data submitted to the Food and Drug Administration (FDA) for emergency use authorization.
On Monday, the FDA fully approved the Pfizer-BioNTech vaccine for patients 16 and older as The Blaze reports, becoming the first vaccine to clear the hurdle from emergency use authorization (EUA).
NBC News reported that Pfizer expects to be able to submit data on toddlers and children younger than 4 not long afterward. Following the FDA’s announcement on Monday, the American Academy of Pediatrics called on the agency to “work aggressively to authorize a vaccine for ages 11 and younger.”
Speaking with NBC’s Lester Holt that evening, CEO Albert Bourla said he expected that Pfizer will soon be wrapping up its “very large studies” on children younger than 12 as soon as September to submit to the FDA to acquire EUA.
He also said he hopes the FDA approval will abate so-called “vaccine hesitancy.”
“Based on the longer-term follow-up date that we submitted, today’s approval for those aged 16 and over affirms the efficacy and safety profile of our vaccine at a time when it is […]
Read the whole story at elizabethjohnston.org
Covid variant BA.5 is spreading. It appears milder but much more contagious and evades natural immunity. Best to boost your immune system with new Z-Dtox and Z-Stack nutraceuticals from our dear friend, the late Dr. Vladimir Zelenko.